Dimensional Fund Advisors LP grew its holdings in Mallinckrodt PLC (NYSE:MNK) by 22.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,077,402 shares of the company’s stock after purchasing an additional 735,529 shares during the period. Dimensional Fund Advisors LP owned approximately 4.91% of Mallinckrodt worth $59,041,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Great West Life Assurance Co. Can increased its stake in shares of Mallinckrodt by 55.4% in the first quarter. Great West Life Assurance Co. Can now owns 125,812 shares of the company’s stock worth $1,822,000 after acquiring an additional 44,826 shares during the last quarter. Spark Investment Management LLC increased its stake in shares of Mallinckrodt by 26.5% in the first quarter. Spark Investment Management LLC now owns 636,700 shares of the company’s stock worth $9,219,000 after acquiring an additional 133,300 shares during the last quarter. Gabelli Funds LLC increased its stake in shares of Mallinckrodt by 12.0% in the first quarter. Gabelli Funds LLC now owns 65,349 shares of the company’s stock worth $946,000 after acquiring an additional 7,000 shares during the last quarter. KBC Group NV increased its stake in shares of Mallinckrodt by 64.2% in the first quarter. KBC Group NV now owns 137,803 shares of the company’s stock worth $1,995,000 after acquiring an additional 53,892 shares during the last quarter. Finally, Neuberger Berman Group LLC acquired a new position in shares of Mallinckrodt in the first quarter worth $7,432,000.
MNK stock opened at $19.27 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.10 and a quick ratio of 1.90. Mallinckrodt PLC has a 52-week low of $11.65 and a 52-week high of $49.12. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 2.57, a PEG ratio of 0.34 and a beta of 1.21.
Mallinckrodt (NYSE:MNK) last released its quarterly earnings results on Tuesday, May 8th. The company reported $1.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.23. Mallinckrodt had a net margin of 57.56% and a return on equity of 11.59%. The company had revenue of $572.60 million during the quarter, compared to analysts’ expectations of $568.78 million. During the same period in the prior year, the company earned $1.04 earnings per share. The business’s quarterly revenue was up 2.2% compared to the same quarter last year. equities analysts anticipate that Mallinckrodt PLC will post 6.23 EPS for the current fiscal year.
In other news, insider Mark Trudeau purchased 3,000 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was bought at an average cost of $15.54 per share, for a total transaction of $46,620.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James E. Flynn sold 312,928 shares of the company’s stock in a transaction dated Wednesday, May 9th. The shares were sold at an average price of $13.39, for a total transaction of $4,190,105.92. The disclosure for this sale can be found here. 1.80% of the stock is owned by corporate insiders.
MNK has been the topic of a number of research reports. Leerink Swann dropped their price target on shares of Mallinckrodt and set a “market perform” rating on the stock in a research note on Monday, April 23rd. ValuEngine downgraded shares of Mallinckrodt from a “hold” rating to a “sell” rating in a research note on Monday, April 2nd. Wells Fargo & Co reissued a “hold” rating on shares of Mallinckrodt in a research report on Thursday, April 12th. B. Riley began coverage on shares of Mallinckrodt in a research report on Wednesday, May 2nd. They set a “neutral” rating and a $15.00 target price on the stock. Finally, SunTrust Banks began coverage on shares of Mallinckrodt in a research report on Wednesday, April 11th. They set a “hold” rating and a $15.00 target price on the stock. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $29.89.
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.